CANF Stock Summary and Trading Ideas (Can Fite Biopharma | AMEX:CANF)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

Can Fite Biopharma trades on the AMEX stock market under the symbol CANF.

As of April 2, 2026, CANF stock price declined to $3.07 with 18,319 million shares trading.

CANF has a beta of 2.61, meaning it tends to be more sensitive to market movements. CANF has a correlation of 0.02 to the broad based SPY ETF.

CANF has a market cap of $6.58 million. This is considered a Sub-Micro Cap stock.

Last quarter Can Fite Biopharma reported $405,000 in Revenue and -$5.97 earnings per share. This beat revenue expectation by $203,000 and exceeded earnings estimates by $4.43.

In the last 3 years, CANF traded as high as $10.40 and as low as $.17.

CANF has outperformed the market in the last year with a return of +119.3%, while the SPY ETF gained +18.2%. In the last 3 month period, CANF beat the market returning +1435.0%, while SPY returned -3.6%. However, in the most recent 2 weeks CANF has underperformed the stock market by returning -10.8%, while SPY returned -0.6%.

CANF support price is $2.86 and resistance is $3.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CANF shares will trade within this expected range on the day.